ANN ARBOR, Mich. (May 6, 2009) — NanoBio Corporation announced today that it will present compelling new data highlighting preclinical milestones in the development of its novel topical treatments for acne and fungal infections. The new data will be delivered in three poster presentations during the 2009 annual meeting of the Society of Investigative Dermatology in Montreal, Canada, from May 6-9, 2009.

Poster Presentations, Room 220 D/E, 10:00 a.m. – 12:00 p.m.:

Thursday, May 7, 2009

• Poster # 464: In-vitro Skin Penetration of Novel Antimicrobial Nanoemulsion Formulations Containing Antifungal Agents

• Poster # 616: In-vitro Susceptibility of Propionibacterium acnes and Skin Penetration of NB-00X Formulations

Saturday, May 9, 2009

• Poster # 465: Lateral Diffusion of Terbinafine Hydrochloride in a Novel Nanoemulsion
  

About NanoBio
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines.

The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Media Contact:
Stacey Holifield/Laura Coluci
Schwartz Communications
nanobio@schwartz-pr.com
(781) 684-0770